UBS Group’s XBiotech XBIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.6K | Hold |
5,035
| – | – | ﹤0.01% | 8491 |
|
|
2026
Q1 | $11.8K | Sell |
5,035
-26
| -0.5% | -$63 | ﹤0.01% | 8280 |
|
|
2025
Q4 | $12.1K | Sell |
5,061
-1,422
| -22% | -$3.51K | ﹤0.01% | 8128 |
|
|
2025
Q3 | $17.2K | Buy |
6,483
+1,432
| +28% | +$4.24K | ﹤0.01% | 8254 |
|
|
2025
Q2 | $15K | Sell |
5,051
-33,262
| -87% | -$96.7K | ﹤0.01% | 8632 |
|
|
2025
Q1 | $124K | Sell |
38,313
-8,218
| -18% | -$28.3K | ﹤0.01% | 6881 |
|
|
2024
Q4 | $184K | Buy |
46,531
+32,106
| +223% | +$219K | ﹤0.01% | 6500 |
|
|
2024
Q3 | $112K | Buy |
14,425
+3,807
| +36% | +$25K | ﹤0.01% | 6274 |
|
|
2024
Q2 | $54.6K | Buy |
10,618
+3,274
| +45% | +$25.3K | ﹤0.01% | 6624 |
|
|
2024
Q1 | $59.7K | Sell |
7,344
-2,105
| -22% | -$12.1K | ﹤0.01% | 6429 |
|
|
2023
Q4 | $37.8K | Buy |
9,449
+4,172
| +79% | +$16.6K | ﹤0.01% | 6708 |
|
|
2023
Q3 | $21.7K | Sell |
5,277
-813
| -13% | -$4.07K | ﹤0.01% | 6762 |
|
|
2023
Q2 | $36.2K | Buy |
6,090
+1,057
| +21% | +$4.77K | ﹤0.01% | 6640 |
|
|
2023
Q1 | $17.4K | Sell |
5,033
-864
| -15% | -$3.22K | ﹤0.01% | 7184 |
|
|
2022
Q4 | $20.7K | Buy |
5,897
+614
| +12% | +$2.09K | ﹤0.01% | 7614 |
|
|
2022
Q3 | $19K | Sell |
5,283
-2,780
| -34% | -$13.1K | ﹤0.01% | 7472 |
|
|
2022
Q2 | $45K | Sell |
8,063
-388
| -5% | -$2.61K | ﹤0.01% | 6006 |
|
|
2022
Q1 | $73K | Sell |
8,451
-3,133
| -27% | -$31.4K | ﹤0.01% | 6140 |
|
|
2021
Q4 | $129K | Buy |
11,584
+5,884
| +103% | +$76.6K | ﹤0.01% | 6067 |
|
|
2021
Q3 | $74K | Buy |
5,700
+2,039
| +56% | +$32.5K | ﹤0.01% | 6048 |
|
|
2021
Q2 | $61K | Sell |
3,661
-3,322
| -48% | -$56.3K | ﹤0.01% | 6254 |
|
|
2021
Q1 | $120K | Sell |
6,983
-1,964
| -22% | -$36.7K | ﹤0.01% | 5827 |
|
|
2020
Q4 | $140K | Buy |
8,947
+5,897
| +193% | +$109K | ﹤0.01% | 5472 |
|
|
2020
Q3 | $58K | Sell |
3,050
-4,401
| -59% | -$76K | ﹤0.01% | 5544 |
|
|
2020
Q2 | $102K | Sell |
7,451
-688
| -8% | -$9.67K | ﹤0.01% | 5290 |
|
|
2020
Q1 | $86K | Sell |
8,139
-11,554
| -59% | -$188K | ﹤0.01% | 5418 |
|
|
2019
Q4 | $368K | Buy |
19,693
+14,594
| +286% | +$188K | ﹤0.01% | 5112 |
|
|
2019
Q3 | $53K | Buy |
+5,099
| New | +$41.5K | ﹤0.01% | 6168 |
|
|
2019
Q1 | – | Sell |
-10,493
| Closed | -$53K | – | 8221 |
|
|
2018
Q4 | $53K | Buy |
+10,493
| New | +$43K | ﹤0.01% | 6042 |
|
|
2018
Q2 | – | Sell |
-191
| Closed | -$1K | – | 8301 |
|
|
2018
Q1 | $1K | Buy |
+191
| New | +$880 | ﹤0.01% | 7671 |
|
|
2017
Q4 | – | Sell |
-229
| Closed | -$1K | – | 8137 |
|
|
2017
Q3 | $1K | Buy |
+229
| New | +$1.08K | ﹤0.01% | 7598 |
|
|
2016
Q3 | – | Sell |
-29,779
| Closed | -$623K | – | 7968 |
|
|
2016
Q2 | $623K | Buy |
+29,779
| New | +$430K | ﹤0.01% | 3743 |
|
|
2016
Q1 | – | Sell |
-2,291
| Closed | -$25K | – | 8251 |
|
|
2015
Q4 | $25K | Buy |
+2,291
| New | +$29.3K | ﹤0.01% | 6523 |
|
|
2015
Q3 | – | Sell |
-465
| Closed | -$8K | – | 8662 |
|
|
2015
Q2 | $8K | Buy |
+465
| New | +$9.64K | ﹤0.01% | 7627 |
|
Other funds holding XBIT
RC
BCM
UBS Group's XBIT Position: Q2 2026 in Review
UBS Group held its XBiotech (XBIT) position steady in Q2 2026 at 5,035 shares worth $11.6K. The position accounts for ﹤0.01% of the portfolio, ranked #8491.
UBS Group first reported a position in XBIT in Q2 2015 and has held it in 34 quarters since. The position peaked at $623K in Q2 2016. 33 funds tracked by Wall St. Rank hold XBIT as of Q2 2026.
- UBS Group held 5,035 shares of XBiotech worth $11.6K as of Q2 2026.
- UBS Group left its XBiotech share count unchanged in Q2 2026.
- XBiotech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8491 holding.
- UBS Group first reported a position in XBiotech in Q2 2015 and has held it in 34 quarters since.
- UBS Group's XBiotech position peaked at $623K in Q2 2016.
- 33 funds tracked by Wall St. Rank held XBiotech as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.